Pfizer breast cancer drug succeeds in mid-stage trial
(Reuters) - Pfizer Inc said its experimental breast cancer drug, in a mid-stage trial, showed a statistically significant improvement in patients' survival rates without their disease worsening.
The drug palbociclib was tested in post-menopausal patients in combination with the hormonal therapy letrozole, and results were compared with patients receiving only letrozole.
(Reporting by Esha Dey in Bangalore; Editing by Ted Kerr)